- In November 2021, Gilead Sciences, Inc. announced the presentation of new clinical and real-world findings at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting, held from November 12–15. The presentations featured the impact of bulevirtide, an investigational therapy for individuals with chronic hepatitis delta virus (HDV) in the U.S., which has received conditional approval in Europe. In addition, real-world insights on global initiatives supporting the World Health Organization’s goal of hepatitis C (HCV) elimination were shared, along with long-term outcomes from ongoing studies focused on the treatment of chronic hepatitis B infection (HBV)
